Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

Table 5 Global response rates in all predefined patients subgroups among MITT patients

Subgroup	Anidulafungin
	Global success %	[n /N]	95% CI
Neutropenic status^a
ANC ≤ 500/mm³	50.0	[1/2]	1.3–98.7
ANC > 500/mm³	75.7	[28/37]	58.8–88.2
Baseline pathogens^b
Candida albicans	71.4	[10/14]	41.9–91.6
C. glabrata	66.7	[4/6]	22.3–95.7
C. parapsilosis	100.0	[4/4]	39.8–100.0
C. rugosa	100.0	[1/1]	2.5–100.0
C. tropicalis	72.2	[13/18]	46.5–90.3
Previous surgery^c
Any surgery	84.6	[11/13]	54.6–98.1
Abdominal surgery	87.5	[7/8]	47.3–99.7
Organ transplantation
Kidney, liver, or heart	0.0	[0/0]	Not applicable
Elderly status
Age ≥ 65 years	58.8	[10/17]	32.9–81.6
Renal insufficiency
Creatinine clearance < 30 ml/min	54.5	[6/11]	23.4–83.3
Use of central venous catheter^c
Yes	81.0	[17/21]	58.1–94.6
Receiving chemotherapy^d
Yes	71.4	[5/7]	29.0–96.3

^a Patients with a missing ANC were not included.
^b A patient could have had more than one baseline pathogen.
^c Up to 1 month before the baseline visit.
^d Up to 3 months before the baseline visit.
Abbreviations used: ANC, absolute neutrophil count; CI, confidence interval; MITT, modified intent-to-treat.

ISSN: 1471-2334